A case of c-kit positive high-grade stromal endometrial sarcoma responding to Imatinib Mesylate.
BACKGROUND
High-grade endometrial stromal sarcoma (HGES) is an aggressive disease with dismal prognosis. Surgery is the standard treatment, and radiotherapy seems to reduce local relapse. No other treatment has proved to be useful in the case of non-resectable diseases.


METHODS
A 41-year-old woman suffering HGES, with positive staining for CD117 (c-kit) and large abdominal and retroperitoneal mass progressing after chemotherapy, was treated with Imatinib Mesylate. After 3 months, objective response was documented and radical surgery performed. Two years after surgical intervention, she is currently free of the disease.


CONCLUSIONS
The response seen with Imatinib should be further investigated in a larger number of cases.
Salvatierra
Alejandro
A
Medical Oncology Service, Institut Català d'Oncologia, Germans Trias i Pujol, Carretera Canyet s/n, 08916 Badalona, Barcelona, Spain.
Tarrats
Antonio
A
Gomez
Carmen
C
Sastre
Josep Maria
JM
Balaña
Carmen
C
D000328:Adult; D000970:Antineoplastic Agents / Q000627:therapeutic use*; D001549:Benzamides; D005260:Female; D006801:Humans; D000068877:Imatinib Mesylate; D010879:Piperazines / Q000627:therapeutic use*; D019009:Proto-Oncogene Proteins c-kit / Q000096:biosynthesis* / Q000235:genetics; D011743:Pyrimidines / Q000627:therapeutic use*; D018203:Sarcoma, Endometrial Stromal / Q000188:drug therapy* / Q000235:genetics / Q000378:metabolism*; D014625:Vaginal Neoplasms / Q000188:drug therapy* / Q000235:genetics / Q000378:metabolism*
D000970:Antineoplastic Agents; D001549:Benzamides; D010879:Piperazines; D011743:Pyrimidines; D000068877:Imatinib Mesylate; D019009:Proto-Oncogene Proteins c-kit